WILLIAM WOODARD: Open Payments
NPI 1104345222 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,144 in 63 payments from 13 companies in 2025. Trend: 2023 $184 · 2024 $33 · 2025 $1,144
Food & beverage: $1,144
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $173 |
| PFIZER INC. | 7 | $170 |
| ABBVIE INC. | 12 | $154 |
| AstraZeneca Pharmaceuticals LP | 9 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $100 |
| Otsuka America Pharmaceutical, Inc. | 2 | $64 |
| Amgen Inc. | 3 | $55 |
| Abbott Laboratories | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $41 |
Products named: AIRSUPRA, UBRELVY, TRINTELLIX, CAPLYTA, Ozempic, ELIQUIS, Wegovy, NURTEC ODT.
Industry payments across AL — which companies pay providers there.
